The initial treatment regimen for EGFR-mutated NSCLC involves the administration of third-generation EGFR-TKI Osimertinib, as recommended by the NCCN Clinical Practice Guidelines for NSCLC 2022 V6. A targeted therapy duration of 56 days will be implemented during the study period.
Free full text: Click here